Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights

02.05.2024 - - Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of 2024; updated combination data expected at the European Society of Hematology (EHA) 2024 ...

Related Keywords

Texas ,United States ,North Carolina ,American ,Mirvetuximab Soravtansine ,Conor Richardson ,Clay Siegall ,Kate Sasser ,Taylor Schreiber ,Exchange Commission ,Ono Pharmaceutical Co Ltd ,Development Rd Expenses ,Shattuck Labs Inc ,American Association For Cancer Research ,Nasdaq ,Cancer Research ,Annual Meeting ,Chief Executive Officer ,Ono Pharma ,Milestones Expected ,Platinum Resistant Ovarian Cancer ,Cancer Cell ,Ono Enter ,Collaboration Agreement ,Appoints Clay Siegall ,Cash Equivalents ,Clinical Trial ,Shattuck Labs ,Agonist Redirected Checkpoint ,Annual Report ,Safe Harbor ,Private Securities Litigation Reform Act ,Media Contact ,Months Ended March ,